Share Twitter LinkedIn Facebook Email Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At MOASC on Jan 19, 2019.
ASH 2025 Lymphoma Highlights: Epcoritamab, S1826, Mosunetuzumab & ctDNA | Dr. Sworder ASH 6 Mins Read
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
